 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Apr 10, 2011 |
| Title |
Correlation of molecular profiles and clinical outcome of stage UICC II colon cancer patients |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Background Published multi-gene classifiers suggested outcome prediction for patients with stage UICC II colon cancer based on different gene expression signatures. However, there is currently no translation of these classifiers for application in routine diagnostic. Therefore, we aimed at validating own and published gene expression signatures employing methods which enable RNA and protein detection in routine diagnostic specimens. Results Immunohistochemistry was applied to 68 stage UICC II colon cancers to determine the protein expression of five selected previously published classifier genes (CDH17, LAT, CA2, EMR3, and TNFRSF11A). Correlation of protein expression data with clinical outcome within a 5-year post-surgery course failed to separate patients with a disease-free follow-up [Group DF] and relapse [Group R]). In addition, RNA from macrodissected tumor samples from 53 of these 68 patients was profiled on Affymetrix GeneChips (HG-U133 Plus 2.0). Prognostic signatures were generated by Nearest Shrunken Centroids with cross-validation. Although gene expression profiling allowed the identification of differentially expressed genes between the groups DF and R, a stable classification and prognosis signature was not discernable in our data. Furthermore, the application of previously published gene signatures consisting of 22 and 19 genes, respectively, to our gene expression data set using ‘global tests’ and leave-one-out cross-validation was unable to predict clinical outcome (prediction rate 75.5% and 64.2%; n.s.). T-stage was the only independent prognostic factor for relapse in multivariate analysis with established clinical and pathological parameters including microsatellite status. Conclusions Our protein and gene expression analyses currently do not support application of molecular classifiers for prediction of clinical outcome in routine diagnostic as a basis for patient-orientated therapy in stage UICC II colon cancer. Further studies are needed to develop prognosis signatures applicable in patient care.
|
| |
|
| Overall design |
53 patients with primary stage UICC II colon cancer treated by elective standard oncological resection were selected. None of the patients received adjuvant chemotherapy. Patients with susceptibility for hereditary colorectal cancer or inflammatory bowel disease were excluded from this study. Routine histopathologic staging of resected specimen was performed by experienced pathologists.
|
| |
|
| Contributor(s) |
Gröne J, Lenze D, Jurinovic V, Hummel M, Seidel H, Leder G, Beckmann G, Sommer A, Grützmann R, Pilarsky C, Mansmann U, Buhr H, Stein H, Hummel M |
| Citation(s) |
21465190 |
| |
| Submission date |
Sep 11, 2009 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Dido Lenze |
| E-mail(s) |
dido.lenze@charite.de
|
| Organization name |
Charité-Universitätsmedizin Berlin
|
| Department |
Pathologie, Campus Benjamin Franklin
|
| Street address |
Hindenburgdamm 30
|
| City |
Berlin |
| ZIP/Postal code |
12200 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (53)
|
|
| Relations |
| BioProject |
PRJNA119367 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE18088_RAW.tar |
243.6 Mb |
(http)(custom) |
TAR (of CEL) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...